2019
DOI: 10.1016/j.jneuroim.2019.577046
|View full text |Cite
|
Sign up to set email alerts
|

RORγT is overexpressed in iNKT and γδ T cells during relapse in relapsing-remitting multiple sclerosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
5

Relationship

3
2

Authors

Journals

citations
Cited by 6 publications
(7 citation statements)
references
References 30 publications
0
6
1
Order By: Relevance
“…An increase was, however, observed after treatment with recombinant IFNβ in a group of patients well responding to this therapy [24]. The former stays in contrast to our results-we observed no significant difference in peripheral blood iNKT percentage between patients in remission or relapse of RRMS and healthy volunteers [30]. Nevertheless, we have observed functional differences-overexpression of RORγT and IL-23R in iNKT both during relapse and remission of RRMS, moreover, we noted a significant rise in iNKT17 during remission.…”
Section: Inkt In Mscontrasting
confidence: 99%
“…An increase was, however, observed after treatment with recombinant IFNβ in a group of patients well responding to this therapy [24]. The former stays in contrast to our results-we observed no significant difference in peripheral blood iNKT percentage between patients in remission or relapse of RRMS and healthy volunteers [30]. Nevertheless, we have observed functional differences-overexpression of RORγT and IL-23R in iNKT both during relapse and remission of RRMS, moreover, we noted a significant rise in iNKT17 during remission.…”
Section: Inkt In Mscontrasting
confidence: 99%
“…Expression of FOXP3, EBI3 and GATA3 in lymphocytes of RRMS patients decreased, with an increased RORC/FOXP3 gene expression ratio [55]. Overexpression of RORC in γδ T cellss and iNKT cellss of RRMS patients in relapse was also detected [56].…”
Section: Jak-stat Pathways In Multiple Sclerosismentioning
confidence: 94%
“…Detailed characteristics are presented in Table 1 . Inclusion criteria were as in our previous study [ 17 ]: I. no other autoimmunological disease diagnosed, II. no glucocorticoid treatment during 4 weeks prior to blood collection, and III.…”
Section: Methodsmentioning
confidence: 99%
“…Staining and flow cytometry was performed as previously [ 17 ]. First, antibodies for surface staining were added to 100 uL of whole peripheral blood.…”
Section: Methodsmentioning
confidence: 99%